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ing, and mobility within
membrane
microdomains.
The reactivity of platelets, which play a key role in the pathogenesis of atherothrombosis, is
tightly regulated. The integral membrane protein tetherin/bone marrow stromal antigen-2
(BST-2) regulates membrane organization, altering both lipid and protein distribution
within the plasma membrane. Because membrane microdomains have an established role
in platelet receptor biology, we sought to characterize the physiological relevance of
tetherin/BST-2 in those cells. To characterize the potential importance of tetherin/BST-2 to
platelet function, we used tetherin/BST-22/2 murine platelets. In the mice, we found
enhanced function and signaling downstream of a subset of membrane
microdomain–expressing receptors, including the P2Y12, TP thromboxane, thrombin, and
GPVI receptors. Preliminary studies in humans have revealed that treatment with
interferon-a (IFN-a), which upregulates platelet tetherin/BST-2 expression, also reduces
adenosine diphosphate–stimulated platelet receptor function and reactivity. A more
comprehensive understanding of how tetherin/BST-2 negatively regulates receptor function
was provided in cell line experiments, where we focused on the therapeutically relevant
P2Y12 receptor (P2Y12R). Tetherin/BST-2 expression reduced both P2Y12R activation and
trafficking, which was accompanied by reduced receptor lateral mobility specifically within
membrane microdomains. In fluorescence lifetime imaging-Förster resonance energy
transfer (FLIM-FRET)–based experiments, agonist stimulation reduced basal association
between P2Y12R and tetherin/BST-2. Notably, the glycosylphosphatidylinositol (GPI) anchor
of tetherin/BST-2 was required for both receptor interaction and observed functional effects.
In summary, we established, for the first time, a fundamental role of the ubiquitously
expressed protein tetherin/BST-2 in negatively regulating membrane
microdomain–expressed platelet receptor function.
Introduction
Platelets are important mediators of thrombosis in both healthy and diseased vessels, which, when
activated by blood vessel injury, form hemostatic thrombi. Pathological activation of platelets can induce
occlusive thrombosis, resulting in ischemic events such as heart attack and stroke.1 In addition, through
their intrinsic ability to store and secrete a multitude of factors, platelets are implicated in the progression
Submitted 12 August 2020; accepted 20 January 2021; published online 1 April 2021.
DOI 10.1182/bloodadvances.2020003182.
Original data may be obtained by e-mail request to the corresponding author
(s.j.mundell@bristol.ac.uk).
The full-text version of this article contains a data supplement.
© 2021 by The American Society of Hematology




 http://ashpublications.org/bloodadvances/article-pdf/5/7/1884/1804165/advancesadv2020003182.pdf by guest on 13 April 2021
of numerous diseases ranging from cancer to viral infection.1,2
Platelet activation is a tightly coordinated process involving the
integrated activation of multiple cell surface–expressed receptors.
As in other cells, this highly coordinated process is dependent on
the localization of a specific repertoire of transducing, enzymatic,
and regulatory kinases and phosphatases that shape signaling
output.
Membrane microdomains (also known as lipid rafts) are small (10-
200 nm), heterogeneous, highly dynamic, ordered membrane
domains enriched in cholesterol, sphingolipids, and gangliosides.3,4
These lipid-enriched regions behave as signaling platforms, mediating
a host of signal transduction, intracellular vesicle trafficking,
cell fate specification, and disease processes. Human platelets
express several surface receptors that have functions that are
dependent on their expression in membrane microdomains, in-
cluding the G protein–coupled thromboxane A2 (TP)5 and P2Y12
receptors (P2Y12Rs).
6-8 Relatively little is known about the identities
of the proteins in platelets or other cells that coordinate surface
receptor distribution into membrane microdomains. Furthermore,
the importance of such proteins in the regulation of receptor
function remains unclear.
Tetherin, also known as bone marrow stromal antigen-2 (BST-2),
CD317, or HM1.24 antigen, is an integral membrane protein with
a novel topology ubiquitously expressed in a variety of cells. After it
was identified as a marker for bone marrow stromal cells9 and
various tumor cells,10 it became clear that tetherin/BST-2 is much
more widely expressed in a variety of cells, including hepatocytes,
pneumocytes, activated T cells, monocytes, plasmacytoid dendritic
cells, ducts of major salivary glands, pancreatic and kidney cells,
and the vascular endothelium.11 Transcriptome analysis12 has
shown that tetherin/BST-2 is also expressed in both human and
mouse platelets. Tetherin/BST-2 is associated with a plethora
of biological processes, including restriction of enveloped virus
release,13 regulation of B-cell growth,14 and organization of
membrane microdomains.14,15 Tetherin/BST-2 is a type 2 single-
pass transmembrane protein with unusual architecture, comprising
a short cytoplasmic tail at the N terminus, followed by a trans-
membrane (TM) region, a coiled-coil extracellular domain (ED)
containing cysteines (C53/C63/C91) that is necessary for
stabilizing dimerization, and a glycosylphosphatidylinositol (GPI)
anchor at the C terminus.16-18 In relation to viral release, this unique
molecular structure allows it to physically tether viral membranes to
the host cell membrane, thereby retaining the virus on the cell
surface.13
In addition to the roles of tetherin/BST-2 in antiviral immunity, we
and others have established that it is an organizer of different
cellular structures and organelles.15 Work from our laboratory was
the first to establish that tetherin/BST-2 is necessary for the
maintenance of the apical actin network and microvilli in polarized
epithelial cells.17 At the cell surface, tetherin/BST-2 is proposed to
decorate the perimeter of membrane microdomains serving as
a picket fence linked to the underlying actin cytoskeleton to stabilize
and organize these regions. The GPI anchor of tetherin localizes the
protein to cholesterol-rich regions of the cell membrane, whereas
the TM domain of the protein sits outside these regions.16 Reduced
tetherin expression has been suggested to change the distribution
of membrane-localized proteins and organization of lipids in the
plasma membrane.15
Although tetherin/BST-2 is ubiquitously expressed, the physiolog-
ical significance of this protein in relation to receptor biology is
unclear. We hypothesized that tetherin/BST-2 expression is
essential for normal platelet receptor function and demonstrate




All materials and reagents used in this study are described in the
supplemental Methods.
Animals
Tetherin/BST-22/2 mice were a kind gift from Paul D. Bieniaz (The
Rockefeller University, New York, NY). Tetherin/BST-2 2/2mice
were maintained on a mixed C57BL/6 background, and littermates
were used as the control, with genotyping of tetherin/BST-22/2, as
previously described.19 All procedures undertaken complied with
the Animals (Scientific Procedures) Act 1986 (licenses 30/2386
and 30/2908) and were approved by the University of Bristol’s local
Research Ethics Committee.
Patient-based experiments
Patients with an essential thrombocythemia (ET) diagnosis,
according to World Health Organization 2001/2008 diagnostic
criteria,20 were enrolled in this study. Four patients had blood
samples collected before initiation of interferon-a2b (IFN-a2b)
therapy, another 4 were treated with pegylated IFN-a2b (40 mg
every other day for 5-23 months). Appropriate informed consent was
obtained from all patients before blood was collected, in accordance
with the Declaration of Helsinki and under a research protocol
approved by the ethics committees of the Chinese Academy of
Medical Sciences and Peking Union Medical College.
Platelet aggregation and ATP secretion
Platelet preparation, aggregation, and adenosine triphosphate
(ATP) secretion were undertaken as previously described21 and
as detailed in the supplemental Methods.
Cell culture and transfection
Both transiently and stably transfected human embryonic kidney
(HEK293) cells were used in this study. Cell culture, plasmid
construct, and transfection procedures are described in the
supplemental Methods.
Measurement of surface protein expression
Platelet surface glycoproteins and thrombin-induced P-selectin
expression were measured by flow cytometry with an Accuri
C6 flow-cytometer (BD Biosciences), with data analyzed by
FACSCalibur.
P2Y1 and P2Y12 surface receptor expression was assessed by
ligand binding using [3H]-2MeSADP, as previously described.22
Tagged surface receptors levels were assessed in HEK293 cells by
enzyme-linked immunosorbent assay, as described,23 and receptor
recycling was measured by flow cytometry as described.24 Details
of the procedures are given in the supplemental Methods.
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Coimmunoprecipitation and immunoblot detection
P2Y12R and tetherin/BST-2 interaction was assessed in both cell
lines and human platelets by coimmunoprecipitation followed by
western blot analysis, as previously described23 and are described
in the supplemental Methods.
Assessment of cAMP accumulation in mouse
platelets and transfected HEK293 cells
Adenosine diphosphate (ADP)–induced inhibition of forskolin (1 mM)-
stimulated cyclic adenosine monophosphate (cAMP) accumula-
tion was performed in washed mouse platelets or in transiently
transfected HEK293 cells, as previously described.22,25 Data are
expressed as the percentage of inhibition of forskolin-stimulated
adenylyl cyclase.
Calcium mobilization assay
ADP-induced calcium mobilization was measured in mouse
platelets by using the Fura-2 LR/AM calcium indicator in a process
described in the supplemental Methods.
Immunofluorescence microscopy
The methods used for preparation of samples (both HEK293 cells
and mouse platelets) for subsequent immunofluorescence micros-
copy are given in detail in the supplemental Methods.
Confocal imaging of platelets or transfected HEK293 cells was
performed with a Leica SP8 confocal microscope (Leica
Microsystems). Excitation was provided by either a 488-nm
(green fluorescent protein [GFP]) or 561-nm (mCherry) laser,
and all images were acquired with a 633 1.4 numeric aperture
(NA) oil-immersion objective.
Fluorescence lifetime imaging (FLIM) was performed on a Leica
TCS SP8 confocal microscope equipped with a PicoHarp
300 time-correlated, single-photon–counting module (Pico-
Quant). A white-light laser with a repetition rate of 20 MHz was
set at 488 nm for GFP excitation. Images were acquired with a 633
1.4 NA oil-immersion objective with GFP fluorescence collected
from 495 to 530 nm, and data were fitted using FLIMfit.26
Live-cell total internal reflection fluorescence (TIRF) microscopy
was performed with a Leica AM TIRF MC system at 37°C in 5%
CO2. Excitation was provided by a 488-nm (GFP) or 561-nm
(mCherry) laser, and all images were acquired with a 1003 1.47
NA, oil-immersion TIRF microscope objective. Images were
captured at 3-second intervals for 1 minute.
Fluorescence recovery after photobleaching (FRAP) was per-
formed on a Leica SP8 confocal microscope. Excitation was
provided by either a 488-nm (GFP), a 561-nm (mCherry), or
a 633-nm (Alexa 647) laser. Images were acquired with a 1003
harmonic compound, plan, apochromat, oil-immersion objective.
Photobleaching was performed after 10 prebleaching scans by
illuminating a circular 2-mm-diameter spot with the 561-nm laser
set to 100% for 5.175 seconds. Images of fluorescence recovery
were captured in successive intervals of 1.725 seconds for
a duration of 260 seconds. Fluorescence recovery was quantified
using ImageJ. The detailed procedures for these imaging methods
are available in supplemental Methods.
Modeling
A variant GPI anchor of tetherin/BST-2 was constructed with
a palmitoyl and oleoyl phospholipid tail.27 The missing residues from
the C terminus of tetherin/BST-2 (Protein Database no. 3NWH)
were built in a helical conformation, and the GPI anchor was
attached via the acidic group of Ser 160. The palmitoyl and oleoyl
tails of the GPI anchor were packed against the P2Y12 structure on
the face presented by the transmembrane helices I, VI, and VII of
P2Y12 in the positions occupied by oleoyl glycerol in the crystal
structure (Protein Database no. 4PXZ).28,29 For clarity, only a single
GPI anchor attached to tetherin/BST-2 is shown. The modeling and
image generation were performed with Chimera (1.11.2).
Bioluminescence resonance energy
transfer measurement
Complementary Rluc-II-Gai-1 and GFP10-Gg2 constructs were
used to measure G protein activation downstream of receptor
stimulation, as described previously30 and detailed in the supple-
mental Methods.
Statistical analysis
Data analyses and determinations of statistical significance were
performed with Prism 7.0 software (GraphPad) and are described
in the supplemental Methods.
Results
Does tetherin/BST-2 affect P2Y12R function
in platelets?
Platelets express several surface receptors, including the P2Y12R,
which necessitates their association with membrane microdomains
for optimal function.5-7 We hypothesized that tetherin/BST-2,
an established regulator of membrane microdomain organization,
could regulate the activity of these receptors. We initially
established that tetherin/BST-2 is expressed in both human and
mouse platelets by both reverse transcription–polymerase chain
reaction (RT-PCR; Figure 1A) and western blot analysis
(Figure 1B). Importantly, tetherin/BST-2 expression was undetect-
able in tetherin/BST-22/2 mouse platelets, validating both primer
and antibody specificity (Figure 1A). There were no obvious
differences between wild-type (WT) and tetherin/BST-22/2 mice
in major hematologic parameters, including platelet count (supple-
mental Figure 1A), mean platelet volume, and platelet distribution
width (data not shown); the expression of surface glycoproteins
(CD41, glycoprotein VI [GPVI], GPI-ba, and PAR-4; supplemental
Figure 1B); and the levels and patterns of oligomers, dimers, and
monomers of the P2Y12Rs in platelets (supplemental Figure 1C).
Ligand binding experiments using [3H]-2MeSADP revealed com-
parable expression of P2Y12Rs in WT vs tetherin/BST-2
2/2
platelets (790 6 59 and 864 6 83 P2Y12Rs per platelet in WT
and tetherin/BST-22/2 platelets).
Given the therapeutic relevance of and our longstanding interest in
P2Y12R biology,
22,23,25,31 we first focused on whether tetherin/BST-
2 regulates P2Y12R function. We observed that ADP-stimulated
platelet aggregation was significantly enhanced in tetherin/BST-22/2
vs littermate control WT mouse platelets (example aggregation
traces in platelet rich plasma [PRP; Figure 1C]) and washed platelets,
with averaged data showing the percentage of maximum aggregation
in washed platelets [Figure 1D]). Intriguingly, in washed platelets at
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Figure 1. Tetherin/BST-2 negatively regulates P2Y12R activities in both platelets and cell lines. (A) PCR and RT-PCR were used to genotype mice. RT-PCR was
performed on total RNA isolated from BST1/1 and tetherin/BST-22/2 mouse platelets, with primers specific for glyceraldehyde-3-phosphate dehydrogenase or tetherin/BST-2.
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a higher ADP concentration (10 mM), platelet aggregation was not
affected in tetherin/BST-22/2 mice, indicative that the effect of
tetherin/BST-2 knockout was surmountable. To further explore this
point, we assessed ADP-stimulated platelet signaling. Given that
ADP activates both the Gq-coupled P2Y1 and Gi-coupled P2Y12Rs
to stimulate platelet aggregation, we assessed signaling outputs
downstream of each receptor. ADP-induced inhibition of forskolin-
stimulated adenylyl cyclase was significantly enhanced in tetherin/
BST-22/2 platelets, with an increase in both the maximum response
and leftward shift of the concentration-response curve (Figure 1E). In
contrast, there was no change in ADP-induced intracellular calcium
responses, which was largely mediated by the G-coupled P2Y1R, in
WT vs tetherin/BST-22/2 platelets (Figure 1F). These data suggest
that tetherin/BST-2 selectively negatively regulates P2Y12R activity in
mouse platelets.
Pilot experiments in human platelets next examined whether
changes in tetherin/BST-2 expression had the potential to affect
ADP-stimulated platelet receptor function. ET is a classic BCR-
ABL12 myeloproliferative neoplasm characterized by overproduc-
tion of mature platelets accompanied by an increased risk of
thrombosis with a risk of major thrombotic events in patients that
ranges from 10% to 29%.32 IFN-a therapy is an approach to
treatment of ET that represses the proliferation of hematopoietic
progenitors, primarily to control platelet counts, thereby reducing
the risk of thrombosis without increasing the tendency to bleed.33
Notably, IFN treatment upregulates tetherin/BST-2 expression in
various cell types across multiple species, including humans.34 We
therefore assessed platelet tetherin/BST-2 levels and ADP-induced
platelet aggregation in 4 enrolled patients with ET before and after
IFN therapy (supplemental Figure 2). Because IFN treatment
decreases the number of platelets, we normalized our platelet
count (3.03 108 cells per milliliter) in our subsequent experiments,
thereby ensuringchanges in platelet reactivity did not occur
because of changes in the number of platelets. IFN therapy
increased tetherin/BST-2 expression (supplemental Figure 2A,
representative blot from 1 patient; supplemental Figure 2B,
quantified data across patients). Along with this increase in
tetherin/BST-2 expression, IFN treatment significantly attenuated
ADP-stimulated platelet reactivity (supplemental Figure 2C, repre-
sentative aggregation traces; supplemental Figure 2D, across
patients). Although preliminary in nature, these data suggest that
tetherin/BST-2 negatively regulates ADP-stimulated platelet activity
in humans.
To further explore tetherin/BST-2-dependent regulation of the
P2Y12R we expressed both proteins in HEK293 cells. HEK293
cells were specifically used, as they are tetherin/BST-2 null,15
enabling the clear establishment of the effects of tetherin/BST-2
expression on receptor function. Notably, tetherin/BST-2 expression
significantly reduced downstream P2Y12R activity with reductions
in both ADP-stimulated inhibition of adenylyl cyclase activity
(Figure 1G) and ERK1/2 phosphorylation (Figure 1H, represen-
tative blot; Figure 1I, quantified data). TIRF microscopy was used
to measure changes in mCherry-HA-P2Y12 surface expression in
HEK293 cells transiently cotransfected with mCherry-HA-P2Y12R
and either BST-2-GFP or GFP vector control (Figure 1J). As in
mouse platelets, changes in tetherin/BST-2 expression did not
significantly affect P2Y12R surface expression (Figure 1J). These
data further confirmed that tetherin/BST-2 negatively regulates
P2Y12R activity.
Does tetherin/BST-2 colocalize and functionally
interact with the P2Y12R?
Initial confocal microscopy in mouse platelets spread on fibrinogen
revealed that tetherin/BST-2 colocalized with the P2Y12R (repre-
sentative images Figure 2A, with image analysis showing pixel
intensity histograms of gray scale images for both the green and red
channels (Figure 2B) and colocalization (Figure 2D). A more
detailed understanding of tetherin/BST-2 colocalization was pro-
vided by experiments on HEK293 cells coexpressing tetherin/BST-
2-GFP and mCherry-HA–tagged P2Y12Rs. Confocal microscopy
indicated that these proteins predominantly associated at the cell
membrane (Figure 2C, representative images; Figure 2D, imaging
analysis). The agonist dependence of any potential receptor and
tetherin/BST-2 interaction was then assessed by immunoprecipi-
tation, first in HEK293 cells and then in human platelets. Cells were
treated with ADP (20 mM; 0, 5, 30, and 60 minutes) solubilized, and
anti-HA immunoprecipitation was performed. Subsequent immuno-
blot analysis revealed a specific association of P2Y12R with
tetherin/BST-2, which was significantly attenuated by receptor
activation (Figure 2E-F). Washed human platelets were treated with
Figure 1. (continued) (B) Washed platelets from humans or BST-21/1 and BST-22/2 mice were solubilized and immunoblotted with tetherin/BST-2 or tubulin-specific
antibodies. Data are representative of at least 4 independent experiments. (C-D) ADP-stimulated platelet aggregation was significantly enhanced in BST-22/2 vs BST-21/1
mice in either platelet-rich plasma (PRP) (C) or washed platelets (D). Representative traces of platelet aggregation in PRP or washed platelets are shown and are
representative of 5 independent experiments. Data from washed platelets were quantified and expressed as maximum platelet aggregation (right). Data represent mean 6
standard error of the mean (SEM) of 5 independent experiments. Maximum platelet aggregation was significantly enhanced in BST-22/2 vs BST-21/1 mice. *P , .05; 2-tailed
Student t test. (E) P2Y12R activity in BST-2
2/2 vs BST-21/1 mouse platelets, as assessed by inhibition of forskolin (1 mM; 10 minutes)-induced cAMP production by ADP
(0.1 nM-100 mM; 10 minutes). Data are means 6 SEM of 4 independent experiments with ADP-stimulated inhibition of adenylyl cyclase activity significantly enhanced in BST-
22/2 vs BST-21/1 mouse platelets (2-way analysis of variance [ANOVA]; P , .01). (F) ADP (0.1-100 mM)-stimulated calcium responses were unchanged in BST-21/1 vs
BST-22/2 mouse platelets. Data are expressed as peak calcium responses (ratio of 340 nm/380 nm readings with Fura-2) and represent the mean 6 SEM of 3 independent
experiments. (G-I) ADP-induced inhibition of forskolin-stimulated cAMP production and ERK1/2 activation were assessed in cells transiently cotransfected with mCherry-
HA–tagged P2Y12R and either tetherin/BST-2-GFP or GFP control vectors. (G) In P2Y12R-expressing cells, ADP-induced (0.1 nM-100 mM; 10 minutes) inhibition of forskolin-
stimulated (1 mM; 10 minutes) cAMP production was significantly attenuated by tetherin/BST-2-GFP overexpression. P , .01; 2-way ANOVA. Data are the mean 6 SEM of 4
independent experiments. (H-I) Activity of ADP (20 mM)-stimulated ERK1/2 activation was also assessed by immunoblot analysis with a p-ERK specific antibody. Total ERK and
a-tubulin served as protein-loading controls. (H) Representative blots of at least 4 independent experiments. (I) Data expressed as p-ERK levels normalized to total ERK. Mean
6 SEM; n 5 4. P2Y12R-stimulated ERK activity was significantly attenuated by tetherin/BST-2-GFP overexpression (*P , .05; 2-way ANOVA). (J) Fluorescence intensity profile
of mCherry-HA-P2Y12R surface expression taken from TIRF microscopy images of HEK293 cells coexpressing tetherin/BST-2-GFP or GFP control (n 5 6 cells over the
course of 6 independent experiments).
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Figure 2. Colocalization and interaction of tetherin/BST-2 with P2Y12R. Tetherin/BST-2 colocalized with the P2Y12R in (A-B,D) mouse platelets and (B-C) HEK293
cells. (A) Representative confocal images of permeabilized mouse platelets spread on fibrinogen and treated with rat anti-mouse tetherin/BST-2 and rabbit anti-P2Y12, followed
by anti-rat Alexa 488 (green)– and anti-rabbit Alexa 546 (red)–conjugated secondary antibodies. Bar represents 10 mm. (B) Pixel intensity histograms of gray scale images (A;
bottom) corresponding to output from green and red channels (A; top). (C) HEK293 cells were transiently transfected with tetherin/BST-2-GFP alone or with either mCherry or
mCherry-HA-P2Y12R. Fixed cell samples were prepared for subsequent confocal microscopy. Representative confocal images of HEK293 cells coexpressing BST-2-GFP
(green) and mCherry (red; top), GFP and mCherry-P2Y12-HA (middle), or BST-2-GFP and mCherry-P2Y12-HA (bottom). Bar represents 1 mm. Images from panels A and C
underwent subsequent quantitative analysis (C; n 5 16 for platelet and n 5 22 for HEK293 cells, across 3 independent experiments). (D) Pearson’s correlation coefficients
(PCCs) in either platelets or in the whole cell vs the membrane or cytoplasm of the cell. The PCCs were significantly higher in membranes vs either the whole cell or
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ADP (10 mM; 30 minutes) and lysed, and anti-P2Y12R immuno-
precipitation was performed. Subsequent immunoblot analysis
revealed a specific association of the P2Y12R with tetherin/BST-
2, which as in the cell lines, was significantly attenuated by receptor
activation (Figure 2G).
To further assess how P2Y12R activation affected interaction with
tetherin/BST-2, we used quantitative Förster resonance energy
transfer (FRET)-based FLIM (FRET-FLIM).26 In these assays, we
assessed fluorescence lifetime in HEK293 cells transiently
cotransfected with tetherin/BST-2-GFP and either mCherry-HA-
P2Y12R or mCherry vector control. Given that our data suggested
that the P2Y12R predominantly colocalized with tetherin/BST-2 at
the plasma membrane, our FLIM images were segmented into the
plasma membrane (Figure 3A) and cytoplasm (supplemental
Figure 3). We focused on the plasma membrane section
(Figure 3A). Coexpression of tetherin/BST-2-GFP and mCherry-
HA-P2Y12R led to a significant reduction of fluorescence life of the
FRET donor in the plasma membrane compared with tetherin/BST-
2-GFP alone or the tetherin/BST-2-GFP1mCherry control (Figure
3A-B; representative images and pooled data, respectively). These
data further demonstrate that the P2Y12R is in close proximity to
and most likely directly interacts with tetherin/BST-2. Notably,
receptor activation by ADP (20 mM; 5, 30, and 60 minutes)
increased donor life. This effect was reversed by removal of ADP by
treatment with apyrase (5 minutes; 1 U/mL; 60 minutes with
apyrase; Figure 3B). These data again suggest that receptor
activation reduced association with tetherin/BST-2. To further
understand the mechanism of agonist-mediated impaired associa-
tion of P2Y12R with tetherin/BST-2, single-cell analysis of the
intensity of intracellular tetherin/BST-2-GFP and mCherry-HA-
P2Y12Rs was undertaken (Figure 3C-E). Cell images captured
before FLIM were segmented for analysis (Figure 3C). The
intracellular intensity of P2Y12R increased after application of the
agonist. The increased intensity was reversed after removal of ADP
by addition of apyrase (Figure 3D). Tetherin/BST-2 levels mean-
while remained relatively constant (Figure 3E) indicating that
receptor activation promoted membrane dissociation of P2Y12R-te-
therin/BST-2 complex, with subsequent receptor internalization.
Tetherin/BST-2-dependent regulation of P2Y12R
surface expression
ADP-induced P2Y12R dissociation with BST-2/tetherin and sub-
sequent internalization were further confirmed with TIRF micros-
copy by measuring fluorescence changes of BST-2-GFP and
mCherryP2Y12-HA in 150-nm penetration depth of the membranes
of cells transiently cotransfected with mCherry-HA-P2Y12R and
either BST-2-GFP or GFP vector control (Figure 4A-D). There was
a gradual but significant agonist-stimulated reduction in P2Y12R
surface levels over time (Figure 4A-C), whereas tetherin/BST-2-
GFP surface expression remained constant (Figure 4A-B,D).
Furthermore, in cells coexpressing P2Y12R and tetherin/BST-2-
GFP, agonist-stimulated loss of surface receptors was attenuated
(Figure 4C).
The P2Y12R is efficiently and rapidly recycled to the cell surface in
platelets.22 To investigate whether these tetherin/BST-2-regulated
changes in surface P2Y12R levels are caused by a defect in
receptor internalization or a potentiation of receptor recycling,
a recycling assay was used with FLAG-tagged-P2Y12R.
24 In this
assay, the receptor is prelabeled, with a calcium sensitive FLAG
antibody (M1) and agonist added to stimulate receptor internaliza-
tion. The surface-bound FLAG antibody is then stripped by
a calcium-free wash, and the recycling of internal FLAG-P2Y12R
is monitored by fluorescence-activated cell sorting after removal of
the agonist. FLAG-P2Y12R efficiently recycled to the cell surface,
with tetherin/BST-2-GFP expression having no effect, suggesting
that tetherin/BST-2 had little effect on the recycling of P2Y12Rs
(Figure 4E). Therefore, tetherin/BST-2 is the likely regulator of
P2Y12R internalization.
In agreement with these experiments in HEK293 cells, ligand-binding
experiments in mouse platelets showed that agonist-induced P2Y12R
surface loss was potentiated in tetherin/BST-22/2 mice (Figure 4F).
Meanwhile, agonist-induced P2Y1R surface loss in mouse platelets
was unaffected by changes in tetherin (Figure 4G). These data
further confirm that tetherin/BST-2 selectively and negatively
regulates specific receptors.
What is the molecular basis of the tetherin/BST-2:
P2Y12R interaction?
We next explored the molecular determinants of tetherin/P2Y12R
interaction. The recently solved crystal structure of the P2Y12R
revealed significant levels of cholesterol packed around the
receptor that are suggested to help pack the receptor in high-
order oligomers.28 Molecular modeling of the P2Y12R with tetherin/
BST-2 revealed the potential for the C-terminal GPI anchor of
tetherin/BST-2 to displace this cholesterol, potentially affecting
receptor function (Figure 5A-B). We therefore explored the
potential importance of the GPI anchor of tetherin/BST-2 in
HEK293 cells by coexpressing FLAG-tagged P2Y12R with either
full-length HA-tagged WT tetherin/BST-2 (WT-HA) or a series
of previously described15 tetherin/BST-2 deletion constructs
(Figure 5C). These included truncations lacking either the
N-terminal region (DN-HA) or the GPI anchor (DGPI-HA) of
tetherin. A further construct (C3A-HA), in which 3 critical cysteine
residues that stabilize tetherin/BST-2 dimer formation through
disulphide bonds are changed to alanines, was also tested.15
FLAG-P2Y12R was coimmunoprecipitated with anti-FLAG affinity
Figure 2. (continued) cytoplasm. *P , .05; Student t test. (E-F) HEK293 cells cotransfected with mCherry-HA-P2Y12 and either tetherin/BST-GFP or GFP control were
treated with ADP (20 mM; 0-60 minutes). The cells were lysed, and the receptors were immunoprecipitated with monoclonal mouse anti-HA-agarose. (E) The samples were
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted for associated anti-GFP (top) and reprobed with an anti-HA antibody
to show the total receptor immunoprecipitated (second gel). Inputs were immunoblotted for GFP (third gel) and anti-a-tubulin to show equal protein loading. Gels are
representative of 3 independent experiments. (F) Quantification of tetherin/BST-2 coimmunoprecipitated with P2Y12R. Data are normalized relative to association of tetherin/
BST-2 with P2Y12R at rest vs agonist stimulated and expressed as means 6 standard error of the mean (n 5 3; *P , .05, Mann-Whitney U test). (G) The P2Y12R was
immunoprecipitated from control or ADP-treated, washed platelets (10 mM; 30 minutes) with a receptor-specific rabbit antibody, as outlined in “Methods.” Immunocomplexes
were resolved by 10% SDS-PAGE and immunoblotted with anti-BST-2 antibody (top gel). Inputs were immunoblotted for P2Y12R (second gel), BST-2 (third gel), and anti-
a-tubulin (bottom gel) to show equal protein loading.
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Figure 3. Tetherin/BST-2 interacts directly with the P2Y12R. HEK293 cells were transiently transfected with tetherin/BST-2-GFP (FRET donor) alone or with either
mCherry or mCherry-HA-P2Y12R (FRET acceptor). Cells coexpressing tetherin/BST-2 and P2Y12R were stimulated with ADP (20 mM; 0-60 minutes) or with ADP (20 mM;
60 minutes), followed by the addition of apyrase (1 U/mL) for 5 minutes. Fixed cell samples were prepared for subsequent microscopy. (A) Representative fluorescence intensity
(gray scale images, top) and corresponding intensity-weighted (pseudocolor, bottom) images of cell membranes at selected time points of measurement. (B) Fluorescence life
measurements of tetherin/BST-2-GFP from cell membrane regions showing association of P2Y12R with tetherin/BST-2. Coexpression of tetherin/BST-2-GFP (donor) with
mCherry-HA-P2Y12R (acceptor) significantly reduced donor vs mCherry life (*P , .05; Student t test) indicative of protein proximity. Addition of ADP (5, 30, and 60 minutes)
significantly increased donor life vs the non–agonist-treated control (§P , .05; Student t test) or after apyrase removal of ADP (€; P , .05; Student t test). (C-E) Agonist-
induced changes in P2Y12R and tetherin/BST-2 intracellular expression were assessed, and the data were normalized and expressed as a percentage of whole-cell fluorophore
intensity. (C) Cell images captured before FLIM were segmented in CellProfiler by using a semiautomatic approach. Identified objects were subsequently reduced in size by
10% to produce complementary masks to define the cell edge and central regions. ADP treatment had no effect on tetherin/BST-2 intracellular expression (D), but promoted
a significant increase in intracellular accumulation of the P2Y12R vs non–agonist-treated control (*P , .05; Student t test) or after apyrase removal of ADP (P , .05; Student
t test; E). (B,D-E) Data points represent a single cell (n . 12 per transfection condition) pooled across 3 independent experiments with line and error bars representing means
6 standard error of the mean .
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Figure 4. Tetherin/BST-2 negatively regulates P2Y12R internalization in both cell lines and mouse platelets. (A) Representative live TIRF microscopy images of
HEK293 cells coexpressing mCherry-HA-P2Y12R (red) and either GFP control (green; top) or tetherin/BST-2-GFP before (green; middle) and after agonist stimulation (ADP;
20 mM; 60 minutes; green; bottom). (B) Fluorescence intensity profiles from lines shown in images from panel A assessing either mCherry (receptor) or GFP (either control or
tetherin/BST-2) surface expression. (C-D) A time course series (0-60 minutes) of the intensity profiles was assessed (n 5 6 cells over the course of 6 independent
experiments), and the ADP-stimulated change in surface mCherry-HA-P2Y12R (C) or tetherin/BST-2-GFP (D) was quantified (percentage change after agonist stimulation;
mean 6 standard error of the mean [SEM]). (E) Assessment of FLAG-P2Y12R recycling by flow cytometry. Receptor-expressing cells prelabeled with anti-FLAG(M1)-FITC
were stimulated with ADP (20 mM; 60 minutes). Surface antibody and ADP were removed by washing with a Ca21-free buffer containing apyrase (0.2 U/mL). P2Y12R
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gel and HA-tetherin/BST-2 interaction assessed by western blot. As
expected, the P2Y12R associated with WT-HA. Interestingly, only
the removal of the GPI anchor of tetherin/BST-2 was found to
disrupt receptor interaction. To exclude the possibility that the loss
of interaction was due to minimal DGPI-HA mutant surface
expression, we assessed receptor interaction with a tetherin/BST-
2 construct in which the GPI anchor was replaced by the CD8a
transmembrane domain (DGPI-CD8a-HA), to mimic the topology of
WT tetherin/BST-2 at the cell surface.15 Again DGPI-CD8a-HA did
not interact with P2Y12R. The GPI anchor of tetherin/BST-2
therefore is critical for receptor interaction. Given that the DGPI-
CD8a-HA construct is unlikely to be localized to membrane
microdomains,35 we suggest that the GPI anchor is critical for
tetherin/BST-2 localization in P2Y12R-containing membrane micro-
domains and for direct interaction with P2Y12R.
To further explore whether the GPI anchor is necessary for tetherin/
BST-2 regulation of P2Y12R signaling, we monitored receptor/
G-protein activation by a standard bioluminescence resonance
energy transfer (BRET)–based approach that measures agonist-
stimulated changes in Ga/bg disassociation by the functionally
validated BRET pair Rluc-II-Gai-1 and GFP10-Gg2.36 Upon
receptor activation, Rluc-II-Gai-1 and GFP10-Gg2 rapidly disasso-
ciated, leading to a decrease in DBRET signal (Figure 5D). As
expected, tetherin/BST-2 expression significantly reduced
P2Y12R-stimulated changes in G-protein activation (Figure 5D).
Expression of either DGPI-HA or DGPI-CD8a-HA constructs had
no effect on P2Y12R activity, confirming the requirement of the GPI
anchor of tetherin/BST-2 to regulate receptor function.
Our molecular modeling suggested that the GPI anchor of tetherin/
BST-2 could displace cholesterol, which influences membrane
integrity and modulates membrane fluidity.37 Could the potential
displacement of this cholesterol affect P2Y12R activity by changing
local membrane fluidity and limit the conformational freedom of
the receptor? To investigate, we performed FRAP experiments
to examine P2Y12R membrane mobility inside and outside of
membrane microdomains in the absence or presence of tetherin/
BST-2. We used cholera toxin subunit B (CT-B) conjugated to
Alexa Fluor 647 which binds to the pentasaccharide chain of the
plasma membrane ganglioside GM-1, enabling selective partition-
ing into membrane microdomains (supplemental Figure 4A). We
therefore photobleached mCherry-HA-P2Y12R
1 regions of trans-
fected HEK293 cells, focusing on CT-B1 or CT-B2 regions of the
plasma membrane and assessed mCherry-HA-P2Y12R FRAP
(supplemental Figure 4B).
Notably, tetherin/BST-2 expression significantly reduced agonist-
stimulated P2Y12R mobility in membrane microdomains (either the
percentage of fluorescence recovery [supplemental Figure 4C] or
the mobile fraction/diffusion coefficient [Figure 5E]). Intriguingly,
tetherin/BST-2 expression appeared to enhance basal, agonist-
independent P2Y12R mobility outside membrane microdomains
although, as in CT-B1 regions, tetherin expression slowed agonist-
dependent receptor mobility. We therefore conclude that tetherin/
BST-2 regulates P2Y12R lateral mobility in the plasma membrane,
decreasing agonist-stimulated lateral diffusion. Because the effec-
tive and coordinated lateral membrane movement of GPCRs is
necessary for effective localization proximal to specific downstream
signaling proteins, we suggest that tetherin/BST-2 in part negatively
regulates receptor signaling by effecting this process.
Does tetherin/BST-2 affect membrane
microdomain–expressed receptor signaling beyond
the P2Y12R?
Thus far, our data have demonstrated that tetherin/BST-2
selectively regulate P2Y12 but not P2Y1R surface expression and
function in platelets. Beyond the P2Y12R, the optimal function of
several platelet-expressed surface receptors is commensal in their
expression in membrane microdomains. The collagen-receptor
GPVI38 and the G-protein–coupled TP receptor5 have been shown
to be associated with membrane microdomains, whereas there is
evidence that the thrombin-stimulated PAR4 receptor associates
with P2Y12.
11 Notably, platelet aggregation was enhanced in
tetherin/BST-22/2 platelets after activation of the PAR4 (Figure 6A,
representative trace), TP (Figure 6B, representative trace) or GPVI
receptor (Figure 6C, representative trace; Figure 6D, mean data for
all agonists showing the percentage of maximum aggregation vs
littermate control W) mouse platelets). We also assessed platelet-
dense granule secretion by measuring ATP release. The level of
secretion of all 3 receptors in tetherin/BST-22/2 platelets was also
enhanced (Figure 6A-C, representative traces, bottom; Figure 6E,
quantified data). Enhanced agonist-stimulated ATP secretion was
not related to increased total levels of ATP in secretory granules in
tetherin/BST-22/2 platelets (supplemental Figure 1D).
Thrombin- and GPVI-dependent platelet activation is in part related
to the stimulation of P2YRs after secretion.39 We therefore asked
whether the enhancement of both CRP- and thrombin-stimulated
platelet aggregation and ATP secretion would be maintained if we
antagonized the P2Y12R. As expected, antagonism of the P2Y12R
with ARC66096 (10 mM) completely abolished CRP (0.4 mM)-
stimulated platelet aggregation and secretion (data not shown)
and partially reduced thrombin-stimulated platelet aggregation
(Figure 6A, example trace, top; Figure 6D, quantified data) and
secretion (Figure 6A, example trace, bottom and Figure 6E,
quantified data). Importantly, thrombin-stimulated platelet aggrega-
tion and secretion in the presence of ARC66096 continued to be
enhanced in tetherin/BST-22/2 platelets. We also assessed
thrombin-induced P-selectin exposure at the platelet surface to
study whether tetherin modulates platelet a-granule secretion.
There was a significant increase in thrombin-stimulated P-selectin
presented at the platelet surface in tetherin/BST-22/2 vs WT
platelets (Figure 6E). Therefore, in summary, our experiments
revealed tetherin/BST-2 to be a negative regulator of the activity of
a series of putative membrane-microdomain–localized receptors.
Figure 4. (continued) recycling was then monitored by flow cytometry. Data represent percentage of recycled P2Y12R (*P , .05; 1-way analysis of variance [ANOVA]). (F-G)
P2Y12, but not P2Y1R internalization, was negatively regulated by tetherin/BST-2 in mouse platelets. BST-2
2/2 and BST-21/1 mouse platelets were stimulated with ADP
(10 mM). P2Y1 and P2Y12 surface receptor levels were measured in fixed, washed platelets, with[
3H]-2MeSADP (100 nM) in the presence of either the P2Y1R antagonist
A3P5P (1 mM) or the P2Y12R antagonist AR-C69931MX (1 mM). Data are expressed as a percentage of surface receptor and represent means 6 SEM of 3 independent
experiments. P2Y12 but not P2Y1R surface loss was potentiated in BST-2
2/2 vs BST-21/1 mouse platelets (P , .05; 2-way ANOVA).






















































































































































Figure 5. The GPI anchor of tetherin/BST-2 is needed to regulate P2Y12R function. (A) An overlay of the P2Y12R crystal structures: antagonist bound (wheat, 4NTJ)
x28
and agonist bound (cyan,4PXZ)xx.29 Protein structures are shown as ribbons, and cholesterol (wheat) and 1-oleoyl-R-glycerol (cyan) are shown in space-filling representations.
TM-helices binding these lipids are labeled I, VI, and VII. (B) A model of the tetherin/BST-2-GPI interaction with P2Y12R. C-terminal part of tetherin/BST-2, magenta ribbon;
GPI anchor in space-filling representations with the lipid tails in the membrane packed against agonist-bound P2Y12R, shown as cyan ribbon. Molecular modeling showing
potential interaction between tetherin/BST-2 and the P2Y12R. (C) The GPI anchor of tetherin/BST-2 is necessary for P2Y12R interaction. HEK293 cells were transfected with
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Discussion
Membrane microdomains play an established role in receptor biology.
For example, in platelets, the P2Y127 and TP receptors,
5 which
amplify platelet activation when stimulated, are both associated with
membrane microdomains. The integral membrane protein tetherin/
BST-2, an established restriction factor for enveloped viruses,
stabilizes membrane microdomains and alters both lipid and protein
distribution within the plasma membrane.14 In this study, we showed,
for the first time, a fundamental role of this ubiquitously expressed
protein in negatively regulating platelet receptor function. Tetherin/
BST-2 regulates the activity of several receptors, with the function of
P2Y12, PAR, TP, and GPVI receptors enhanced in tetherin/BST-2
2/2
mice. Notably, this effect of tetherin is receptor specific, with no
changes in the function of receptors (eg, P2Y1R) that are not found in
these membrane microdomains. Furthermore, in relation to cardio-
vascular disease, we demonstrated in patients that IFN treatment
upregulates platelet expression of tetherin/BST-2 with an accompa-
nying reduction in platelet reactivity.
Our detailed molecular experiments demonstrated a complex mode
of action of tetherin/BST-2 that in part requires the C-terminal GPI
anchor of the protein and involves changes in surface receptor
mobility. Biochemical fractionation, receptor immunoprecipitation,
and confocal imaging techniques demonstrated that there was
constitutive association between the P2Y12R and tetherin/BST-2 in
both cells and, importantly, in human platelets. Through a FRET-FLIM
approach, we demonstrated that surface association between
receptor and tetherin/BST-2 is reversibly reduced in the presence
of agonist. After disassociation, tetherin/BST-2 remained at the cell
surface, whereas P2Y12R was internalized. We have previously
established that the P2Y12R interacts with a range of intracellular
binding partners, after phosphorylation of G-protein–coupled re-
ceptor kinase, which coordinates receptor internalization via a cla-
thrin-mediated pathway.40 Detailed further study is now needed to
understand the relationship between tetherin/BST-2 and its effect on
P2Y12R interaction with other regulatory binding partners.
Results of molecular modeling experiments suggested that the GPI
anchor of tetherin/BST-2 plays a role in receptor interaction, with 3
TM helices (I, VI, and VII) of the P2Y12R potentially involved in
interaction with the GPI anchor. Intriguingly, these are the same
helices that showed the most perturbation between the agonist-
and antagonist-bound crystal structures. We speculate, therefore,
that tetherin/BST-2 modulates the conformational freedom of the
P2Y12R to perturb agonist responsiveness. However, it should be
kept in mind that these regions of the P2Y12R are involved in
receptor dimerization in the antagonist-bound crystal structure,
although we have no evidence of significant changes in levels of
receptor oligomerization.
The key role of the GPI anchor of tetherin/BST-2 in receptor
interaction was confirmed in mutagenesis experiments. Could the
GPI anchor of tetherin displace cholesterol from membrane
microdomains to affect P2Y12R activity? Cholesterol depletion
from cell membranes is known to attenuate P2Y12R activity.
6
Notably, the crystal structure of the P2Y12R indicates that
cholesterol packs around the receptor to maintain conformational
integrity.28 However, given that the GPI anchor is also necessary for
effective localization of tetherin/BST-2 to membrane microdomains,
we can at this time only speculate that displacement of cholesterol
by the GPI anchor of tetherin/BST-2 is a direct regulator of P2Y12R
activity.
Intriguingly, we found that tetherin/BST-2 expression limited
agonist-stimulated lateral diffusion of the P2Y12R within membrane
microdomains. Expression of high-order oligomeric complexes
containing the P2Y12R in membrane microdomains is necessary
for effective receptor signaling.6 Given that agonist-stimulated
internalization is necessary to maintain P2Y12R signaling,
22 does
tetherin/BST-2 limit the movement of non–desensitized receptors
into or desensitized receptors out of membrane microdomains?
Two studies have established that the lateral distribution and
mobility of receptors in the membrane plane bring signaling partners
efficiently into transient or stable contact.41,42 Various models of
GPCR membrane organization and associated trajectories have
been suggested with receptors that freely diffuse over long
distances in the membrane.43 However, their movement is also
restricted within membrane microdomains. Further detailed study is
now needed to investigate movement of P2Y12Rs and whether the
Figure 5. (continued) FLAG-P2Y12 alone or in combination with a variety of HA-tagged constructs, including full-length tetherin/BST-2, 2 truncations lacking either the
N-terminal region (DN-HA) or the GPI anchor (DGPI-HA) of tetherin/BST-2, tetherin/BST-2 triple cysteine→alanine mutant (C3A-HA), or a tetherin/BST-CD8 construct in
which the GPI anchor has been replaced by the CD8a transmembrane domain (DGPI-CD8-HA). Cells were lysed, and the receptor was immunoprecipitated by using
monoclonal mouse anti-FLAG M2 Affinity Gel. Samples were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotted for associated anti-HA
(top gel). Inputs were immunoblotted for anti-HA to show protein loading (middle gel) and immunoprecipitates reprobed with anti-FLAG antibody (rabbit) to show the total
receptor immunoprecipitated (bottom gel). (D) The GPI anchor of tetherin/BST-2 is essential for tetherin/BST-2–dependent regulation of P2Y12R activity. HEK293 cells were
cotransfected with 2:1:1 ratios of Gi protein constructs (Rluc-II-tagged Gai-1/Gb1/GFP10-tagged Gg2), FLAG-P2Y12R and either HA-tagged tetherin/BST-2 constructs (HA-
WT, DGPI-HA or CD8-DGPI-HA) or pcDNA3.1 control. P2Y12R activity was assessed by agonist-stimulated changes in BRET between Gai-1-Rluc-II and GFP10-Gg2 in living
cells. Data are expressed as DBRET by subtracting the BRET values obtained in the vehicle condition from the one measured with ADP and represent mean 6 standard error
of the mean of 4 independent experiments. Shown are concentration-dependence of P2Y12R activation (ADP; 1 nM-100 mM; top) and time-dependent activation of the
P2Y12R by ADP (20 mM; bottom). Only full-length tetherin/BST-2-HA expression attenuated P2Y12R activity (both top and bottom; *P , .05; 2-way ANOVA tetherin/BST-2 vs
pDNA3.1 control). (E) Tetherin/BST-2 attenuatedP2Y12R mobility in membrane microdomains after receptor activation, as assessed by FRAP. HEK293 cells expressing
mCherry-HA-P2Y12R alone or coexpressing mCherry-P2Y12-HA and BST-2-GFP, were stained with the membrane microdomain marker cholera toxin-B (CTB). Confocal
FRAP was performed at 37°C in live cells with a 2-mm diameter bleach spot (supplemental Figure 4B) on CTB1 (yellow circles) or negative regions (cyan circles) of the cell
membrane. FRAP was subsequently assessed. In agonist-treated cells ADP (20 mM) was added 5 minutes before FRAP. Data were collected from .9 cells from 3
independent experiments and are expressed as either the percentage of normalized mCherry-P2Y12-HA final mobile fraction (left) or the diffusion coefficient (mm2/s; right).
Tetherin/BST-2 expression significantly attenuated P2Y12R mobility into CTB
1 membrane microdomain regions in ADP-treated cells (left; *P , .05 Mann-Whitney U test in
tetherin/BST-2 expressing vs nonexpressing cells in membrane microdomains in ADP-treated cells (right); *P , .05; Student t test; tetherin/BST-2–expressing vs
nonexpressing cells in membrane microdomains in ADP-treated cells).




 http://ashpublications.org/bloodadvances/article-pdf/5/7/1884/1804165/advancesadv2020003182.pdf by guest on 13 April 2021
formation by tetherin/BST-2 of a physical barrier or picket fence
linked to the underlying actin cytoskeleton at the perimeter of
membrane microdomains is critical for function.
Our experiments in mouse platelets and cell lines have therefore
established tetherin/BST-2 as a regulator of receptor function.
Previous studies have demonstrated that patients who receive IFN,
which is used in the treatment of a variety of clinical conditions,
including ET, leads to an upregulation of tetherin/BST-2 expression
in various cell types.13 Intriguing pilot studies in human platelets
showed that IFN treatment of patients with ET increased tetherin/
BST-2 expression was accompanied by decreased ADP-stimulated
platelet reactivity. ET is characterized by overproduction of mature
platelets and an increased risk of thrombosis.32 The goals of
cytoreductive therapy for ET are primarily to reduce the risk of
thrombosis without increasing the tendency toward bleeding and
to minimize the risk of progression to myelofibrosis or acute
leukemia.32 The results of our pilot study suggest that IFN reduces
risk of thrombosis, not only by decreasing the number of platelets,
but also by directly attenuating their function. There are reported
reductions in platelet reactivity after administration of IFN for the
treatment of melanoma44 and hepatitis C,45 with the suggestion
that reductions in platelet reactivity limit platelet participation in
disease progression (ie, by limiting the inflammatory process
involved in hepatitis C or by reducing or preventing the formation
of melanoma metastases). In addition, given the effects on platelet
reactivity, it should be noted that IFN treatment could have
implications in the event of accidental injury or elective surgery.
Clearly, this notion requires further extensive study, well beyond the
scope of this current work.
In summary, these findings have broad implications for our
understanding of platelet receptor signaling from the membrane
microdomain, indicating that tetherin/BST-2 plays a key role in
regulating output from these sites and may represent a useful
therapeutic target for regulating platelet receptor and therefore
platelet reactivity.
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Figure 6. Tetherin/BST-2 negatively regulates other membrane microdomain–expressed receptor functions in mouse platelets. Thrombin (A)-, TP thromboxane
(B)-, and CRP (C)-stimulated platelet aggregation was significantly enhanced in BST-22/2 vs BST-21/1 mice in washed platelets. Representative traces from 3 independent
experiments showing platelet aggregation (top) and ATP secretion (bottom) in response to thrombin in the absence and presence of the P2Y12 receptor antagonist
(ARC66096; 10 mM), U46619 or CRP. (D-E) Data were quantified and expressed as maximum aggregation (D) and ATP secretion (E). Data represent mean 6 standard error
of the mean (SEM) of 3 independent experiments. *P , .05; 2-tailed Student t test. (F) Platelet a-granule secretion was assessed by measuring thrombin (0.03 m/mL)-
stimulated P-selectin expression by flow cytometry. Data represent mean 6 SEM of 3 independent experiments. *P , .05; 2-tailed Student t test.
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